Kinetics, Role and Therapeutic Implications of Endogenous Soluble form of Receptor for Advanced Glycation end Products (sRAGE) in Diabetes

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|8|10|1138-1143

ISSN： 1389-4501

Source： Current Drug Targets, Vol.8, Iss.10, 2007-10, pp. : 1138-1143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication

By  

Current Pharmaceutical Design, Vol. 14, Iss. 5, 2008-02 ,pp. : 487-495

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy

By  

Current Drug Discovery Technologies, Vol. 3, Iss. 1, 2006-03 ,pp. : 83-88

Bentham Science Publishers

Access to resources Recommend Favorite

Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target

By  

Current Medicinal Chemistry, Vol. 13, Iss. 17, 2006-07 ,pp. : 1971-1978

Bentham Science Publishers

Access to resources Recommend Favorite

Effect of S100A12 and soluble receptor for advanced glycation end products on the occurrence of severe acute pancreatitis

By  

Journal of Digestive Diseases, Vol. 17, Iss. 7, 2016-07 ,pp. : 475-482

John Wiley & Sons Inc

Access to resources Recommend Favorite

Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes

By  

Current Drug Targets, Vol. 12, Iss. 14, 2011-12 ,pp. : 2096-2102

Bentham Science Publishers

Access to resources Recommend Favorite